Form 4 RenovoRx Inc For: 24 June
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
RenovoRx Inc (RNXT)
The RenovoRx share price today is 0.958, view NASDAQ RNXT stock exchange data. Track the latest RenovoRx share price with real-time updates on RNXT stock performance including market cap, day range, 52-week range and dividend yield. Access RNXT charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.923
0.970
52 wk Range
0.701
1.450
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9230.970
52 wk Range
0.7011.450
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RNXT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
7.030
Upside
+633.82%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
RenovoRx CFO Mark Voll buys $19,690 in common stock- Investing.com
RenovoRx earnings missed, revenue topped estimates- Investing.com
- Form 4 RenovoRx Inc For: 24 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.030
(+633.82% Upside)
RenovoRx Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue hit $563K, beating forecast of $542.7K with 136% sequential and 186% YoY growth; stock rose 3.65% in pre-market trading
- Company doubled active cancer centers from 8 to 16, targeting 36 centers by end of 2026 from pipeline of 48 prospective locations
- Secured $10M private placement financing; cash position strengthened to $12.4M with gross margin of 85.1% and controlled SG&A at $2.7M
- Q1 revenue represents over half of total 2025 annual revenue, signaling accelerated commercial momentum in oncology device sector
- TIGeR-PaC phase III trial ongoing; management cited strong execution and expanding network as key drivers for continued growth trajectory
Last Updated: 15-05-2026, 02:48 am
Read Full TranscriptEarnings
Latest Release
14-05-2026
EPS / Forecast
-0.09 / -0.08
Revenue / Forecast
560K / 542.67K
Compare RNXT to Peers and Sector
Metrics to compare | RNXT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNXTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.5x | −6.5x | −0.3x | |
PEG Ratio | −0.25 | −0.43 | 0.00 | |
Price/Book | 3.8x | 4.3x | 2.6x | |
Price / LTM Sales | 28.5x | 15.1x | 3.0x | |
Upside (Analyst Target) | - | 75.9% | 56.6% | |
Fair Value Upside | Unlock | 10.0% | 10.2% | Unlock |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the RenovoRx (RNXT) Share Price Today?
The RenovoRx share price today is 0.958.
What is the current RenovoRx (RNXT) share price and day range?
As of 31-07-2026, the RenovoRx share price is 0.958, with a previous close of 0.941. The share price has ranged from 0.923 to 0.970 today, while the 52-week range spans from 0.701 to 1.450.
What Is the RenovoRx Market Cap?
As of today, RenovoRx market cap is 42.450M.
What Is the RenovoRx (RNXT) Share Price Target?
The average 12-month share price target for RenovoRx is 7.030, with a high estimate of 14 and a low estimate of 3. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +633.82% Upside potential.
What Is RenovoRx's Earnings Per Share (TTM)?
The RenovoRx EPS (TTM) is -0.332.
When Is the Next RenovoRx Earnings Date?
RenovoRx will release its next earnings report on 12-08-2026.
From a Technical Analysis Perspective, Is RNXT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does RenovoRx Trade On?
RenovoRx is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for RenovoRx?
The stock symbol for RenovoRx is "RNXT."
How Many Times Has RenovoRx Stock Split?
RenovoRx has split 0 times.
How Many Employees Does RenovoRx Have?
RenovoRx has 17 employees.
What Is the RNXT Premarket Price?
RNXT's last pre-market stock price is 0.905. The pre-market share volume is 7,220.000, and the stock has changed by -0.036, or -3.830%.
What Is the RNXT After Hours Price?
RNXT's last after hours stock price is 0.939, the stock has changed by -0.019, or -1.990%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.